; and (2) in addition to any other remuneration that such person receives by reason of the nonexclusive marketing, distribution, sale, or use of the drug, biological product, or manufacturing process for a drug or biological product. (c) Application This section shall apply only with respect to the marketing, distribution, sale, or use of a drug, a biological product, or a manufacturing process for a drug or biological product that occurs on or after October 1, 2018. 6. Fund for medical innovation prizes (a) Establishment There is hereby established in the Treasury of the United States a revolving fund to be known as the Fund for Medical Innovation Prizes , which shall consist of amounts appropriated to the Fund and amounts credited to the Fund under subsection (c). (b) Availability of funds Amounts in the Fund shall be available to the Board, subject to section 17(c), for the purpose of carrying out this Act. (c) Amounts credited to the Fund The Secretary of the Treasury shall credit to the Fund the interest on, and the proceeds from sale or redemption of, obligations held in the Fund. 7. Board of trustees for the Fund (a) Establishment There is hereby established (as a permanent, independent establishment in the executive branch) a Board of Trustees for the Fund for Medical Innovation Prizes. (b) Membership The Board shall be composed of 13 members, including— (1) the Administrator of the Centers for Medicare & Medicaid Services; (2) the Commissioner of Food and Drugs; (3) the Director of the National Institutes of Health; (4) the Director of the Centers for Disease Control and Prevention; and (5) 9 individuals to be appointed by the President, with the advice and consent of the Senate, of which— (A) 2 shall be representatives of businesses that provide health insurance to employees; (B) 2 shall be representatives of entities that provide health insurance and contribute to the co-funding of the Fund for Medical Innovation Prizes under section 17